AZD2014 + Everolimus
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Clear Cell Renal Carcinoma
Conditions
Metastatic Clear Cell Renal Carcinoma
Trial Timeline
Feb 1, 2013 → Nov 1, 2015
NCT ID
NCT01793636About AZD2014 + Everolimus
AZD2014 + Everolimus is a phase 2 stage product being developed by AstraZeneca for Metastatic Clear Cell Renal Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01793636. Target conditions include Metastatic Clear Cell Renal Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Clear Cell Renal Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01793636 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic Clear Cell Renal Carcinoma